Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00865566 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 2
- Development phase
- 2,504
- Enrollment target
NCT00865566 is a Phase 2 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 2,504 participants.
The verdict
NCT00865566, a Phase 2 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2,504 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of a VRC DNA/rAd5 vaccine regimen in healthy, circumcised men and male-to-female (MTF) transgender persons who have sex with men. NOTES: As of April 2013, all vaccinations in this study have been stopped. As of June 2017, this study has been closed.
Interventions
- BIOLOGICAL DNA plasmid vaccine
- BIOLOGICAL Recombinant adenoviral serotype 5 (rAD5) vector vaccine
- BIOLOGICAL DNA vaccine placebo
- BIOLOGICAL HIV-1 recombinant adenovirus vaccine placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,504 participants |
| Start Date | 2009-05 |
| Est. Completion | 2017-10-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00865566
The ClinicalTrials.gov registry entry for NCT00865566 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2,504 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which DNA plasmid vaccine is the first listed.
NCT00865566 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00865566 about?
NCT00865566 is a clinical study titled "Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men". The purpose of this study is to determine the safety and efficacy of a VRC DNA/rAd5 vaccine regimen in healthy, circumcised men and male-to-female (MTF) transgender persons who have sex with men. NOTES: As of April 2013, all vaccinations in this study have been stopped. As of June 2017, this stud...
What is the current status of trial NCT00865566?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2,504 participants. The study started on 2009-05. Estimated completion is 2017-10-06.
What interventions are being tested in trial NCT00865566?
The interventions under investigation include: DNA plasmid vaccine (BIOLOGICAL), Recombinant adenoviral serotype 5 (rAD5) vector vaccine (BIOLOGICAL), DNA vaccine placebo (BIOLOGICAL), HIV-1 recombinant adenovirus vaccine placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT00865566?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.